Navigation Links
Developments in TACE and SIRT treatment in patients
Date:4/26/2013

Amsterdam, The Netherlands, Friday 26 April 2013: Data from a number of clinical trials presented today at the International Liver Congress 2013 shed new light on the use of TACE and SIRT in the treatment of hepatocellular carcinoma (HCC).

Transarterial chemoembolization (TACE) is a technique in which small particles designed to block blood vessels mixed or coated with chemotherapeutic drugs are injected directly into an artery supplying the tumour; it has become a standard treatment in selected patients with HCC.

New data presented today has identified a scoring system which defines those HCC patients who achieve the most benefit from TACE. An Assessment for Retreatment with TACE (or ART-score) was developed based on the impact of the initial TACE session on parameters of liver function and tumour response, and their impact on overall survival (overall survival; log rank test).

The ART-score differentiated two groups (0-1.5 points; ≥2.5 points) with distinct differences in prognosis (median overall survival: 23.7 months vs. 6.6 months; p< 0.001) which was confirmed in an independent external validation cohort. In addition, a higher ART-score was associated with major adverse events after the second TACE session (p=0.011).

EASL Vice-Secretary, Prof. Markus Peck-Radosavljevic commented: "These findings represent an important discovery as they will enable physicians to identify and treat those HCC patients who will benefit from repeat TACE sessions. Furthermore, rounds of ineffective treatment, as well as any associated side effects and complications, can be avoided for those patients who are not likely to respond."

While TACE is the standard-of-care treatment for intermediate-stage HCC, selective Internal Radiotherapy Treatment (SIRT) is more commonly used to treat patients with advanced-stage HCC, or those who are poor candidates for, or have failed TACE. However, data from SIRTACE, a separate, open-label, multi-centre pilot study suggest that a single-session of SIRT is as safe and effective as multiple sessions of TACE in a typical TACE patient cohort with unresectable HCC.

Patients were randomised to receive either TACE (n=15) or SIRT (n=13). Patients received a mean of 3.4 TACE interventions (median 2; range 1-11) or 1 SIRT procedure. Treatment response was assessed by local (using RECIST 1.0) and independent central (RECIST 1.1 and mRECIST) review. Median progression-free survival (RECIST 1.1) was 5.5 months (95%CI: 1.6- not reached) for TACE and 4.1 months (95%CI: 2.3-9.9) for SIRT (p=0.411). Overall survival did not differ by procedure (p=0.244).

The similar efficacy and safety of these two procedures presents a challenge for the design of a phase III trial for intermediate-stage HCC in terms of whether to use TACE or SIRT as the preferred treatment technique.

Finally, the SORAMIC European multicentre phase II clinical trial also showcased at the congress, evaluated the efficacy and safety of using a combination of SIRT and sorafenib for the treatment of HCC.

Data from the interim safety analysis has confirmed that SIRT as a sequential approach followed by an escalation scheme for sorafenib does not lead to increased toxicity. Interim analysis of the data showed a total number of adverse events of 196 and 220 in the combination and control arm, with grade 3-5 adverse events reaching 42 and 49, respectively (p>0.05).

SORAMIC continues to recruit and investigators are hopeful that the combination of SIRT and sorafenib will be shown to significantly enhance survival over sorafenib alone without increasing toxicity thus enabling to design large Phase III clinical trials.

Disclaimer: the data referenced in this release is based on the submitted abstract. More recent data may be presented at the International Liver Congress 2013.


'/>"/>

Contact: Dimple Natali
easlpressoffice@cohnwolfe.com
44-079-001-38904
European Association for the Study of the Liver
Source:Eurekalert

Related medicine news :

1. New developments reveal a molecule with a promising function in terms of cancer treatment.
2. Spread of Cancer May be Reduced by Maximizing Melatonin by Blocking Blue Light Says Photonic Developments LLC
3. New Way to Fight the Winter Blues (SAD): Use Glasses from Photonic Developments LLC that Block Blue Light
4. DePuy ASR Hip Replacement Lawsuit Lawyers at Wright & Schulte LLC Report Latest Developments in DePuy ASR Hip Implant Recall Lawsuits
5. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
6. Clinical insight improves treatment with new lung cancer drug
7. Rapid Asthma Treatment in ER May Prevent Admission
8. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
9. Breast cancer patients suffer treatment-related side effects long after completing care
10. Mayo Clinic offers newly approved treatment for acid reflux disease
11. Mobile Stroke Units Might Trim Time to Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
(Date:10/12/2017)... GRAND RAPIDS, Mich. (PRWEB) , ... October 12, ... ... OnSite Wellness, has been named one of Michigan’s 2017 Best and Brightest in ... Best and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/9/2017)... 8, 2017 Dealmed Medical Supplies, ... medical equipment, supplies, drugs, vaccines, and specialty medical products ... an agreement to acquire Vantage Medical Supplies, a major ... Holtsville, New York . ... and emerging medical practices, will operate under the Dealmed ...
Breaking Medicine Technology: